Table 3.
Outcomes in patients treated before and after the implementation of AN.
| Outcomes | AN− (n = 29) |
AN+ (n = 47) |
p-Value |
|---|---|---|---|
| Any Hemorrhagic transformation (%) | 6.9% | 10.6% | 0.584 |
| Symptomatic Intracranial Hemorrhage (%) | 3.4% | 0.0% | 0.200 |
| NIHSS-score 2 h, points (median, IQR) | 2 (0.5–3.5) | 3 (1–5.25) | 0.230 |
| NIHSS 24 h, points (median, IQR) | 1 (0–4) | 1.5 (0–4) | 0.697 |
| Discharge NIHSS (median, IQR) | 0 (0–2.5) | 0 (0–3) | 0.977 |
| 3-month mRS-score, points (median, IQR) | 2 (1–4) | 3 (1–5) | 0.614 *** |
| 3-month Functional Independence (%) * | 82.1% | 89.1% | 0.394 |
| 3-month Favorable Functional Outcome (%) ** | 75.0% | 78.3% | 0.746 |
| 3-month Mortality (%) | 0.0% | 4.3% | 0.263 |
National Institute of Health Stroke Scale, NIHSS. * mRS-scores of 0–2. ** mRS-scores of 0–1. *** Cochran–Mantel–Haenszel test.